The Government formalized the measure that relaxes dollar loans for companies through Decree 736/2026, published in the Official Gazette, with the aim of supporting companies in accessing foreign currency credits. This decision could have a positive impact on the Argentine economy, especially on the business sector.
The Argentine Government formalized the measure that relaxes dollar loans for companies, which could lead to an increase in the number of credits granted to companies in foreign currency. This was done through Decree 736/2026, published in the Official Gazette.
The measure aims to support companies in accessing foreign currency credits, which could improve their ability to compete in the international market. Dollar loans are an important tool for companies that need financing for expansion or investment.
The relaxation of dollar loans could have a positive impact on the Argentine economy, especially on the business sector. This is because companies could access credits at lower interest rates and more favorable conditions, allowing them to invest in their growth and expansion.
The Government's decision to relax dollar loans for companies occurs in a complex economic context, where the number of companies requesting foreign currency credits has increased significantly. This is because companies need to access financing to maintain their competitiveness in the international market.
The measure could also have an impact on the dollar exchange rate, as the increased number of foreign currency credits could generate a higher demand for dollars. However, it is essential to note that the dollar exchange rate is influenced by multiple factors, making it difficult to predict the exact impact of the measure on the currency's exchange rate.
El Banco Central permite que las financieras usen hasta el 15 % de sus depósitos en dólares para otorgar préstamos a empresas, una medida que busca reactivar la inversión productiva.
La acción de Moderna subió 95 % después de que su vacuna de ARN mensajero contra el cáncer, desarrollada con Merck, obtuviera el primer resultado positivo en una fase 3.
El pronóstico más audaz de Wall Street sitúa al S&P 500 en 9.000 para fin de 2027, un 17 % por encima del nivel actual.
